Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.90 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL15393192 | 1.00 | SLC34A1 (0.90) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL2806090 | 1.00 | SLC34A1 (0.90) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL17459504 | 1.00 | SLC34A1 (0.90) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL4003820 | 1.00 | SLC34A1 (0.90) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL1851174 | 1.00 | SLC34A1 (0.90) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL6408390 | 1.00 | SLC34A1 (0.90) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL5955535 | 1.00 | SLC34A1 (0.90) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL14119492 | 1.00 | SLC34A1 (0.90) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL17042378 | 1.00 | SLC34A1 (0.90) | SLC34A1LMNAKDM4ECYP2C19KMT2A | |
| Phosphoric Acid SCHEMBL5955338 | 1.00 | SLC34A1 (0.90) | SLC34A1LMNAKDM4ECYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112522225-A | Method for modifying uricase by polyethylene glycol | 鲁南制药集团股份有限公司 | 2021-03-19 | — | — | CN | disclosed |
| CN-105087704-B | Controllable multi-enzyme cascade reaction for synthesizing optical pure allylic epoxy ketone or alcohol | 中国科学院成都生物研究所 | 2020-02-21 | — | — | CN | disclosed |
| US-20190010149-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| US-9469630-B2 | Sustained-release formulation for injection | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20160158228-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-2629775-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012053654-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-26 | — | — | WO | disclosed |
| US-20120091022-A1 | SUSTAINED-RELEASE FORMULATION FOR INJECTION | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20030186400-A1 | Method for producing optically active 2-hydroxycycloalkanecarboxylic acid ester | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-10-02 | — | — | US | disclosed |
| EP-1323827-A2 | Method for producing optically active 2-hydroxycycloalkanecarboxylic acid ester | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-07-02 | — | — | EP | disclosed |
| EP-0461526-B1 | Hair treating composition | KAO CORP (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5219562-A | Thioglyceryl ethers; permanent wave solutions with reduced odor and skin irritation | KAO CORPORATION (JP) | 1993-06-15 | — | — | US | disclosed |
| US-5137884-A | Antibiotics | MERCK & CO., INC. (US) | 1992-08-11 | — | — | US | disclosed |
| EP-0461526-A2 | Hair treating composition | KAO CORPORATION (JP) | 1991-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186400-A1 | Method for producing optically active 2-hydroxycycloalkanecarboxylic acid ester | HACL2, APEH, HAO2 | SLC34A1 3081/4885LMNA 1919/4885KDM4E 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.